Patents by Inventor Christoph Rosenbohm
Christoph Rosenbohm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11591594Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.Type: GrantFiled: March 6, 2020Date of Patent: February 28, 2023Assignee: Roche Innovation Center Copenhagen A/SInventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
-
Patent number: 11555050Abstract: The present invention relates to the field of oligonucleotide conjugates and to methods of synthesis thereof. In the present method a low-water content solvent environment allows a more efficient conjugation, reducing the amount of conjugate moiety needed and increasing the conjugation reaction speed.Type: GrantFiled: February 28, 2020Date of Patent: January 17, 2023Assignee: Roche Innovation Center Copenhagen A/SInventors: Dennis Jul Hansen, Christoph Rosenbohm, Michael Meldgaard
-
Patent number: 11505569Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.Type: GrantFiled: August 6, 2020Date of Patent: November 22, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Nanna Albaek, Jacob Ravn, Christoph Rosenbohm
-
Publication number: 20210040137Abstract: The present invention relates to the field of oligonucleotide conjugates and to methods of synthesis thereof. In the present method a low-water content solvent environment allows a more efficient conjugation, reducing the amount of conjugate moiety needed and increasing the conjugation reaction speed.Type: ApplicationFiled: February 28, 2020Publication date: February 11, 2021Inventors: Dennis Jul Hansen, Christoph Rosenbohm, Michael Meldgaard
-
Publication number: 20210017214Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.Type: ApplicationFiled: August 6, 2020Publication date: January 21, 2021Inventors: Nanna Albaek, Jacob Ravn, Christoph Rosenbohm
-
Publication number: 20200407392Abstract: The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid derivatives of the formula I can be used in preloaded solid supports of the formula III and as that serve as suitable start material for oligonucleotide synthesis.Type: ApplicationFiled: September 10, 2020Publication date: December 31, 2020Applicant: Hoffmann-La Roche Inc.Inventors: KURT PUENTENER, CHRISTOPH ROSENBOHM, FILIPPO SLADOJEVICH
-
Patent number: 10815481Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.Type: GrantFiled: December 16, 2015Date of Patent: October 27, 2020Assignee: Roche Innovation Center Copenhagen A/SInventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
-
Publication number: 20200318109Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I 18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.Type: ApplicationFiled: March 6, 2020Publication date: October 8, 2020Inventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
-
Patent number: 10577388Abstract: The present invention relates to the field of oligonucleotide conjugates and to methods of synthesis thereof. In the present method a low-water content solvent environment allows a more efficient conjugation, reducing the amount of conjugate moiety needed and increasing the conjugation reaction speed.Type: GrantFiled: September 29, 2016Date of Patent: March 3, 2020Assignee: Roche Innovation Center Copenhagen A/SInventors: Dennis Jul Hansen, Christoph Rosenbohm, Michael Meldgaard
-
Publication number: 20190055550Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/118267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.Type: ApplicationFiled: August 22, 2016Publication date: February 21, 2019Applicant: Roche Innovation Center Copenhagen A/SInventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
-
Publication number: 20180305392Abstract: The present invention relates to the field of oligonucleotide conjugates and to methods of synthesis thereof. In the present method a low-water content solvent environment allows a more efficient conjugation, reducing the amount of conjugate moiety needed and increasing the conjugation reaction speed.Type: ApplicationFiled: September 29, 2016Publication date: October 25, 2018Inventors: Dennis Jul Hansen, Christoph Rosenbohm, Michael Meldgaard
-
Publication number: 20180237777Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: ApplicationFiled: January 5, 2018Publication date: August 23, 2018Applicant: Roche Innovation Center Copenhagen A/SInventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
-
Publication number: 20180237778Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: ApplicationFiled: January 5, 2018Publication date: August 23, 2018Applicant: Roche Innovation Center Copenhagen A/SInventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
-
Patent number: 9994850Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: GrantFiled: June 9, 2017Date of Patent: June 12, 2018Assignee: Roche Innovation Center Copenhagen A/SInventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
-
Publication number: 20180112217Abstract: The present invention provides stereodefined phosphorothioate LNA oligonucleotide, comprising at least one stereodefined phosphorothioate linkage between a LNA nucleoside and a subsequent (3?) nucleoside.Type: ApplicationFiled: November 18, 2015Publication date: April 26, 2018Inventors: Henrik Frydenlund Hansen, Troels Koch, Nanna Albaek, Jacob Ravn, Christoph Rosenbohm, Peter Hagedorn
-
Patent number: 9951333Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: GrantFiled: June 9, 2017Date of Patent: April 24, 2018Assignee: Roche Innovation Center Copenhagen A/SInventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Charlotte Albaek Thrue, Majken Westergaard, Christoph Rosenbohm
-
Patent number: 9890383Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: GrantFiled: June 9, 2017Date of Patent: February 13, 2018Assignee: Roche Innovation Center Copenhagen A/SInventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
-
Publication number: 20180016575Abstract: The present relates to LNA gapmer antisense oligonucleotides which comprise stereodefined phosphoramidite linkages. The use of stereodefined phosphoramidite linkages in LNA gapmers has been found to provide enhanced RNaseH activity, and modifying stereospecificity enables the reduced toxicity, altered biodistribution, and enhanced mismatch discrimination.Type: ApplicationFiled: November 18, 2015Publication date: January 18, 2018Inventors: Henrik Frydenlund Hansen, Troels Koch, Nanna Albaek, Jacob Ravn, Christoph Rosenbohm, Peter Hagedorn
-
Publication number: 20170342412Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: ApplicationFiled: June 9, 2017Publication date: November 30, 2017Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
-
Publication number: 20170342413Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.Type: ApplicationFiled: June 9, 2017Publication date: November 30, 2017Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard